SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 75,000 Shares of Stock

SiBone (NASDAQ:SIBN – Get Free Report) CEO Laura Francis sold 75,000 shares of the stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $25.30, for a total value of $1,897,500.00. Following the transaction, the chief executive officer owned 304,256 shares in the company, valued at $7,697,676.80. This trade represents a 19.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Laura Francis also recently made the following trade(s):

  • On Monday, October 12th, Laura Francis sold 38,006 shares of SiBone stock. The shares were sold at an average price of $20.05, for a total transaction of $762,020.30.
  • On Monday, August 24th, Laura Francis sold 25,972 shares of SiBone stock. The stock was sold at an average price of $20.12, for a total value of $522,556.64.
  • On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total value of $78,538.46.
  • On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total transaction of $1,009,662.64.

SiBone Stock Down 0.1%

SiBone stock opened at $24.24 on Friday. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $25.92. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of -78.19 and a beta of 0.64. The company’s 50 day simple moving average is $19.81 and its 200 day simple moving average is $16.59.

SiBone (NASDAQ:SIBN – Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.05. SiBone had a negative return on equity of 7.62% and a negative net margin of 6.20%. The business had revenue of $55.70 million during the quarter, compared to the consensus estimate of $55.31 million. As a group, sell-side analysts anticipate that SiBone will post -0.34 EPS for the current year.

SiBone News Summary

Here are the key news stories impacting SiBone this week:

  • Positive Sentiment: Quarterly results beat expectations and lifted shares. Si-Bone reported a third-quarter loss of $0.08 per share, narrower than the $0.13 loss analysts expected, while revenue of $55.7 million modestly exceeded estimates. The results were followed by a reported 8.7% stock jump. Article on SIBN’s post-earnings gain
  • Positive Sentiment: Analyst support helped drive the stock to a 52-week high. TD Cowen raised its price target to $23 from $20, and UBS raised its target to $26 from $25; both maintained Buy ratings. SIBN reached a 52-week high amid the favorable coverage and earnings momentum. Article on SIBN’s 52-week high and analyst upgrade TD Cowen price-target article UBS price-target article
  • Neutral Sentiment: Full-year revenue guidance was reaffirmed. Si-Bone’s 2026 revenue outlook of $231 million to $233 million was broadly in line with analyst expectations, offering limited new information for investors. Si-Bone Q3 results and guidance
  • Negative Sentiment: Multiple insiders sold shares. CEO Laura Francis sold 75,000 shares, SVP Michael Pisetsky sold 36,241, Anshul Maheshwari sold 3,247, and director Jeffrey Dunn sold 20,000. The sales may weigh on sentiment, although each retained shares after the transactions. CEO sale filing SVP sale filing Maheshwari sale filing Dunn sale filing

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. First Light Asset Management LLC increased its stake in shares of SiBone by 51.8% in the 2nd quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock valued at $132,649,000 after acquiring an additional 2,774,795 shares during the last quarter. Granahan Investment Management LLC grew its stake in SiBone by 97.6% during the first quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock valued at $21,965,000 after acquiring an additional 858,942 shares in the last quarter. Paradigm Capital Management Inc. NY lifted its position in SiBone by 113.3% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,126,500 shares of the company’s stock valued at $14,228,000 after purchasing an additional 598,300 shares during the last quarter. Renaissance Technologies LLC grew its holdings in SiBone by 101.6% in the first quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock worth $5,969,000 after purchasing an additional 238,219 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in SiBone by 41.8% in the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock valued at $7,816,000 after acquiring an additional 182,465 shares during the period. 98.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. TD Cowen boosted their price target on SiBone from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Tuesday. Wall Street Zen raised SiBone from a “hold” rating to a “buy” rating in a research report on Saturday. Truist Financial raised their price target on SiBone from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Citigroup reiterated a “market outperform” rating on shares of SiBone in a research report on Tuesday. Finally, UBS Group increased their price target on SiBone from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, SiBone has a consensus rating of “Moderate Buy” and an average target price of $25.00.

View Our Latest Stock Report on SiBone

About SiBone

(Get Free Report)

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.

Recommended Stories

Insider Buying and Selling by Quarter for SiBone (NASDAQ:SIBN)

Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.